case_images: PMC8529000_01
case_images: FDG-PET/CT. FDG uptake was detected in almost all bone segments (A) and in breast lesions (B) before treatment.
case_images: fonc-11-651723-g001.jpg
case_images: PMC8529000_01_fonc-11-651723-g001.jpg
case_images: f1
case_images: An 18-fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) showed uptake with activation of the bone marrow in all bone segments, a nuanced uptake in bilateral breast and a pelvic ascitic effusion ( Figures 1A ,  B ).
case_images: FDG-PET/CT. Completely disappeared bone (A) and breast (B) uptake was observed after five months of AI, LH-RHa and CDK4/6 inhibitor.
case_images: fonc-11-651723-g002.jpg
case_images: PMC8529000_01_fonc-11-651723-g002.jpg
case_images: f2
case_images: PET/CT scan showed the resolution of the hypermetabolic breast tumors and bone metastatic foci with the disappearance of the ascitic effusion ( Figures 2A, B ). Patient's subsequent PET/CT imaging every 6 months confirmed complete response to ongoing treatment with last PET/CT performed in June 2020.
case_images: Relevant clinical data and therapies from diagnosis till now organized as a timeline.
case_images: fonc-11-651723-g003.jpg
case_images: PMC8529000_01_fonc-11-651723-g003.jpg
case_images: f3
case_images: Timeline of relevant clinical data and therapies are presented in  Figure 3 .